HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Talbird, S. E. Articles by Sander, B. Search for Related Content PubMed PubMed Citation Articles by Talbird, S. E. Articles by Sander, B.

SANDRA E. TALBIRD, M.S.P.H., is Associate Director, Health Economics; and A<NITA J. BROGAN, PH.D., is Senior Director, Health Economics, RTI Health Solutions, Research Triangle Park, NC. ALEKSANDER P. WINIARSKI, PHARM.D., is Product Knowledge Manager, Roche Laboratories, Inc., Nutley, NJ. BEATE SANDER, M.B.A. M.EC.DEV., RN, is a student, Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada, and Researcher, Division of Clinical Decision-Making and Health Care Research, University Health Network, Toronto.

Address correspondence to Ms. Talbird at RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, NC 27709-2194 (stalbird{at}rti.org).

Purpose. The cost-effectiveness of treating influenzalike illness (ILI) with oseltamivir in the United States was assessed. Methods. A decision-analysis model was developed with a one-year time horizon to assess the cost-effectiveness of oseltamivir compared with usual care from societal and payer perspectives for four patient populations: high-risk adults, healthy adults, elderly adults, and children. The model used efficacy data from oseltamivir clinical trials and other published literature and assumed oseltamivir was effective only in individuals infected with influenza virus not resistant to oseltamivir and treated within 48 hours of symptom onset. Direct medical costs were based on resources used; indirect costs were estimated based on time lost from work due to illness and premature mortality. Base-case estimates were tested in one-way sensitivity and variability analyses. Results. From a societal perspective, oseltamivir was cost-effective across all populations modeled, with an incremental cost per quality-adjusted life-year gained of $5,388, $6,317, $7,652, and $16,176 for high-risk adults, children, elderly adults, and healthy adults, respectively. Results were similar from a payer perspective. When indirect costs were included (for all populations except elderly adults), oseltamivir was cost saving. In sensitivity analyses, oseltamivir remained cost-effective across all patient populations for all values tested, except the probability of developing influenza-related pneumonia. Variability analyses showed that oseltamivir remained cost-effective under most scenarios tested. Conclusion. Base-case results and sensitivity analyses from a decision-analysis model found that treatment of ILI with oseltamivir was cost-effective compared with usual care from U.S. payer and societal perspectives in all patient populations studied when only direct costs were considered. Index terms: Antivirals; Geriatrics; Influenza; Oseltamivir; Pediatrics; Pharmacoeconomics

 

This article has been cited by other articles:

				N. Khazeni, D. W. Hutton, A. M. Garber, N. Hupert, and D. K. Owens Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009 Ann Intern Med, December 15, 2009; 151(12): 829 - 839. [Abstract] [Full Text] [PDF]

				N. Khazeni, D. W. Hutton, A. M. Garber, and D. K. Owens Effectiveness and Cost-Effectiveness of Expanded Antiviral Prophylaxis and Adjuvanted Vaccination Strategies for an Influenza A (H5N1) Pandemic Ann Intern Med, December 15, 2009; 151(12): 840 - 853. [Abstract] [Full Text] [PDF]

				N. Khazeni, D. W. Hutton, A. M. Garber, and D. K. Owens Effectiveness and Cost-Effectiveness of Expanded Antiviral Prophylaxis and Adjuvanted Vaccination Strategies for an Influenza A (H5N1) Pandemic Ann Intern Med, October 5, 2009; (2009) 0000605-200912150-00156v1. [Abstract] [Full Text]

				N. Khazeni, D. W. Hutton, A. M. Garber, N. Hupert, and D. K. Owens Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009 Ann Intern Med, October 5, 2009; (2009) 0000605-200912150-00157v1. [Abstract] [Full Text]